RU2012150453A - Иммуностимулирующие олигонуклеотиды - Google Patents
Иммуностимулирующие олигонуклеотиды Download PDFInfo
- Publication number
- RU2012150453A RU2012150453A RU2012150453/10A RU2012150453A RU2012150453A RU 2012150453 A RU2012150453 A RU 2012150453A RU 2012150453/10 A RU2012150453/10 A RU 2012150453/10A RU 2012150453 A RU2012150453 A RU 2012150453A RU 2012150453 A RU2012150453 A RU 2012150453A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- immunogenic composition
- composition according
- bacterium
- causes
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 38
- 102000036639 antigens Human genes 0.000 claims abstract 38
- 108091007433 antigens Proteins 0.000 claims abstract 38
- 230000002163 immunogen Effects 0.000 claims abstract 33
- 239000000203 mixture Substances 0.000 claims abstract 33
- 241000894006 Bacteria Species 0.000 claims abstract 9
- 230000003308 immunostimulating effect Effects 0.000 claims abstract 7
- 230000001580 bacterial effect Effects 0.000 claims abstract 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract 4
- 208000002925 dental caries Diseases 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims abstract 4
- 230000000813 microbial effect Effects 0.000 claims abstract 4
- 229960002715 nicotine Drugs 0.000 claims abstract 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000003071 parasitic effect Effects 0.000 claims abstract 4
- 208000028169 periodontal disease Diseases 0.000 claims abstract 4
- 230000003612 virological effect Effects 0.000 claims abstract 4
- 241000186044 Actinomyces viscosus Species 0.000 claims abstract 2
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims abstract 2
- 208000031886 HIV Infections Diseases 0.000 claims abstract 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract 2
- 241000186660 Lactobacillus Species 0.000 claims abstract 2
- 241000605862 Porphyromonas gingivalis Species 0.000 claims abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract 2
- 241000194019 Streptococcus mutans Species 0.000 claims abstract 2
- 241000194023 Streptococcus sanguinis Species 0.000 claims abstract 2
- 241000193987 Streptococcus sobrinus Species 0.000 claims abstract 2
- 230000029662 T-helper 1 type immune response Effects 0.000 claims abstract 2
- 229960003920 cocaine Drugs 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229940039696 lactobacillus Drugs 0.000 claims abstract 2
- 201000004792 malaria Diseases 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims abstract 2
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 2
- 244000045947 parasite Species 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims 5
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 4
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 2
- 229960002733 gamolenic acid Drugs 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000003970 toll like receptor agonist Substances 0.000 claims 2
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108010040721 Flagellin Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 229940124614 TLR 8 agonist Drugs 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940124669 imidazoquinoline Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
Abstract
1. Иммуногенная композиция, содержащая антиген и иммуностимулирующий олигонуклеотид, состоящий из нуклеотидной последовательности 5' TCGTCGTTTTTCGGTGCTTTT 3' (SEQ ID NO:1), дополнительно содержащая фармацевтически приемлемый носитель.2. Иммуногенная композиция по п.1, где иммуностимулирующий олигонуклеотид находится в количестве, эффективном для индукции антиген-специфического иммунного ответа.3. Иммуногенная композиция по п.2, где индуцированный антиген-специфический иммунный ответ представляет собой Th1-иммунный ответ.4. Иммуногенная композиция по п.1, где антиген представляет собой микробный антиген, аутоантиген или вещество, вызывающее привыкание, выбранное из кокаина и никотина.5. Иммуногенная композиция по п.4, где микробный антиген представляет собой бактериальный антиген, вирусный антиген или паразитарный антиген.6. Иммуногенная композиция по п.5, где:а) бактериальный антиген ассоциирован с Staphylococcus aureus, бактерией, вызывающей кариес зубов, или бактерией, вызывающей периодонтальное заболевание;б) вирусный антиген ассоциирован с респираторно-синцитиальным вирусом (RSV), вирусом простого герпеса 1, вирусом простого герпеса 2, вирусом иммунодефицита человека-1 (HIV-1) или HIV-2, илив) паразитарный антиген ассоциирован с паразитом, вызывающим малярию.7. Иммуногенная композиция по п.6, где:а) бактерия, которая вызывает кариес зубов, представляет собой Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis, Lactobacillus acidophilis или Actinomyces viscosus; илиб) бактерия, которая вызывает периодонтальное заболевание, представляет собой Porphyromonas gingivalis или Actinobacillus actinomycetemcomitans.8. Иммуногенная композиция по п.4, где аутоантиген представляет собой опухолевый антиген, антиген, ас
Claims (22)
1. Иммуногенная композиция, содержащая антиген и иммуностимулирующий олигонуклеотид, состоящий из нуклеотидной последовательности 5' TCGTCGTTTTTCGGTGCTTTT 3' (SEQ ID NO:1), дополнительно содержащая фармацевтически приемлемый носитель.
2. Иммуногенная композиция по п.1, где иммуностимулирующий олигонуклеотид находится в количестве, эффективном для индукции антиген-специфического иммунного ответа.
3. Иммуногенная композиция по п.2, где индуцированный антиген-специфический иммунный ответ представляет собой Th1-иммунный ответ.
4. Иммуногенная композиция по п.1, где антиген представляет собой микробный антиген, аутоантиген или вещество, вызывающее привыкание, выбранное из кокаина и никотина.
5. Иммуногенная композиция по п.4, где микробный антиген представляет собой бактериальный антиген, вирусный антиген или паразитарный антиген.
6. Иммуногенная композиция по п.5, где:
а) бактериальный антиген ассоциирован с Staphylococcus aureus, бактерией, вызывающей кариес зубов, или бактерией, вызывающей периодонтальное заболевание;
б) вирусный антиген ассоциирован с респираторно-синцитиальным вирусом (RSV), вирусом простого герпеса 1, вирусом простого герпеса 2, вирусом иммунодефицита человека-1 (HIV-1) или HIV-2, или
в) паразитарный антиген ассоциирован с паразитом, вызывающим малярию.
7. Иммуногенная композиция по п.6, где:
а) бактерия, которая вызывает кариес зубов, представляет собой Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis, Lactobacillus acidophilis или Actinomyces viscosus; или
б) бактерия, которая вызывает периодонтальное заболевание, представляет собой Porphyromonas gingivalis или Actinobacillus actinomycetemcomitans.
8. Иммуногенная композиция по п.4, где аутоантиген представляет собой опухолевый антиген, антиген, ассоциированный с болезнью Альцгеймера, антиген против человеческого антитела, антиген, который экспрессируется из человеческих эндогенных ретровирусных элементов, или никотиновый гаптен, конъюгированный с носителем.
9. Иммуногенная композиция по п.8, где:
а) опухолевый антиген представляет собой HER2 (рецептор человеческого эпидермального фактора роста 2), MAGE (антиген, ассоциированный с меланомой), NY-ESO (раково-тестикулярный антиген), PSA (простатспецифический антиген), СЕА (карциноэмбриональный антиген) или вариант EGFR (рецептор эпителиального фактора роста);
б) антиген, ассоциированный с болезнью Альцгеймера, представляет собой tau или β-амилоид;
в) антиген представляет собой IgE; или
г) носитель, с которым конъюгирован никотиновый гаптен, представляет собой дифтерийный токсин (DT).
10. Иммуногенная композиция по п.1, где антиген представляет собой пептид, рекомбинантный белок, очищенный белок, цельный убитый патоген, живой ослабленный вирус или вирусный вектор, живую ослабленную бактерию или бактериальный вектор, полисахарид, гаптен или кодируется плазмидной ДНК.
11. Иммуногенная композиция по п.1, где антиген конъюгирован с носителем.
12. Иммуногенная композиция по п.11, где носитель представляет собой дифтерийный токсин (DT) или вирусоподобную частицу, где вирусоподобная частица представляет собой РНК-фаг Q-β, поверхностный антиген гепатита В (HBsAg) или коровый антиген гепатита В (HBcAg).
13. Иммуногенная композиция по п.1, дополнительно содержащая один или более адъювантов.
14. Иммуногенная композиция по п.13, где адъювант представляет собой агонист Toll-подобного рецептора (TLR), который не является TLR9.
15. Иммуногенная композиция по п.14, где агонист представляет собой агонист TLR3, TLR4, TLR5, TLR7 или TLR8.
16. Иммуногенная композиция по п.15, где:
а) агонист TLR3 представляет собой стабилизированную poly I:C (полиинозиновая-полицитидиловая кислота);
б) агонист TLR4 представляет собой производное липополисахарида (LPS), выбранное из MPL (монофосфориллипид А) или GLA (гамма-линоленовая кислота);
в) агонист TLR5 представляет собой флагеллин; или
г) агонист TLR7 или TLR8 представляет собой небольшую молекулу имидазохинолинового семейства.
17. Иммуногенная композиция по п.13, где адъювант представляет собой соль алюминия, иммуностимулирующий комплекс (ISCOM), эмульсию масло-в-воде или вода-в-масле, липосому или систему доставки, выбранную из наночастицы или микрочастицы
18. Иммуногенная композиция по п.17, где соль алюминия представляет собой гидрат окиси алюминия.
19. Иммуногенная композиция по п.1, где
а) иммуностимулирующий олигонуклеотид содержит одну или более фосфоротиоатных связей; или
б) иммуностимулирующий олигонуклеотид содержит пиримидин-пуриновый динуклеотид.
20. Иммуногенная композиция по п.1, где иммуногенная композиция приготовлена для введения.
21. Иммуногенная композиция по п.1, где:
а) иммуногенная композиция приготовлена для введения парентеральным путем, где парентеральный путь представляет собой внутримышечный, подкожный, интрадермальный, внутривенный или интраперитонеальный путь; или
б) иммуногенная композиция приготовлена для введения местным путем, где местный путь представляет собой кожный, трансдермальный пути или путь через поверхность слизистой оболочки.
22. Иммуногенная композиция по п.21, где путь через поверхность слизистой оболочки представляет собой пероральный, интраназальный, интравагинальный, интраректальный, интрабуккальный или внутриглазной пути.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12102208P | 2008-12-09 | 2008-12-09 | |
US61/121,022 | 2008-12-09 | ||
US18179909P | 2009-05-28 | 2009-05-28 | |
US61/181,799 | 2009-05-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011122418/10A Division RU2477753C2 (ru) | 2008-12-09 | 2009-12-01 | Иммуностимулирующие олигонуклеотиды |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2012150453A true RU2012150453A (ru) | 2014-06-10 |
RU2610690C2 RU2610690C2 (ru) | 2017-02-14 |
Family
ID=41716468
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011122418/10A RU2477753C2 (ru) | 2008-12-09 | 2009-12-01 | Иммуностимулирующие олигонуклеотиды |
RU2012150453A RU2610690C2 (ru) | 2008-12-09 | 2012-11-27 | Иммуностимулирующие олигонуклеотиды |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011122418/10A RU2477753C2 (ru) | 2008-12-09 | 2009-12-01 | Иммуностимулирующие олигонуклеотиды |
Country Status (27)
Country | Link |
---|---|
US (1) | US9453059B2 (ru) |
EP (2) | EP2376107B1 (ru) |
JP (1) | JP5016733B2 (ru) |
KR (1) | KR101329374B1 (ru) |
CN (1) | CN102333538B (ru) |
AR (1) | AR074501A1 (ru) |
AU (1) | AU2009325926B2 (ru) |
BR (1) | BRPI0923341B8 (ru) |
CA (1) | CA2745096C (ru) |
CO (1) | CO6382137A2 (ru) |
DK (2) | DK2376107T3 (ru) |
ES (2) | ES2481040T3 (ru) |
HK (1) | HK1165325A1 (ru) |
HU (1) | HUE027823T2 (ru) |
IL (1) | IL213162A (ru) |
MX (1) | MX2011006088A (ru) |
MY (2) | MY172421A (ru) |
NZ (1) | NZ593220A (ru) |
PE (1) | PE20110998A1 (ru) |
PL (2) | PL2376107T3 (ru) |
PT (1) | PT2376107E (ru) |
RU (2) | RU2477753C2 (ru) |
SG (1) | SG171829A1 (ru) |
SI (2) | SI2759306T1 (ru) |
TW (1) | TWI370740B (ru) |
WO (1) | WO2010067262A1 (ru) |
ZA (1) | ZA201104048B (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ593220A (en) * | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
SI2699587T1 (sl) | 2011-04-22 | 2019-08-30 | Wyeth Llc | Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka |
SG10201610251PA (en) | 2012-06-08 | 2017-01-27 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
SG10201704611WA (en) | 2012-12-13 | 2017-07-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
SG11201507462QA (en) * | 2013-03-14 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
BR112015027327B1 (pt) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
AU2014268836B2 (en) | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
AR097029A1 (es) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
MY178288A (en) | 2013-09-20 | 2020-10-07 | Nat Inst Biomedical Innovation Health & Nutrition | Complex containing oligonucleotide having immunopotentiating activity and use thereof |
CN105925583B (zh) * | 2013-11-08 | 2019-05-17 | 上海交通大学 | 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途 |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
JP2017537619A (ja) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | 球状核酸ナノ粒子複合体の配列特異的細胞内取込 |
AU2016332266B2 (en) * | 2015-09-30 | 2020-05-07 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
KR20210068601A (ko) * | 2016-06-02 | 2021-06-09 | 조에티스 서비시즈 엘엘씨 | 감염성 기관지염에 대한 백신 |
US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
AU2018313636A1 (en) * | 2017-08-10 | 2020-03-26 | Yisheng Biopharma (Singapore) Pte Ltd | A composition for treating and/or preventing hepatitis B virus infection and the use thereof |
CN111629750A (zh) | 2017-09-28 | 2020-09-04 | 辉瑞公司 | 用于引发针对艰难梭菌的免疫应答的组合物和方法 |
EP3946444A1 (en) | 2019-04-01 | 2022-02-09 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
AU2020403296A1 (en) * | 2019-12-13 | 2022-07-07 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Immunostimulatory composition and use thereof |
WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
CN112877275B (zh) * | 2021-02-04 | 2023-03-31 | 中国农业科学院兰州兽医研究所 | Hdac2基因敲除的bhk-21细胞系及其构建方法和应用 |
CN115252772A (zh) * | 2021-04-30 | 2022-11-01 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
TWI802177B (zh) * | 2021-12-27 | 2023-05-11 | 景岳生物科技股份有限公司 | 副乾酪乳桿菌gmnl-32之核苷酸用於製備調節免疫能力之醫藥組合物的用途 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
WO1999013676A2 (en) | 1997-09-12 | 1999-03-18 | Williams Wireless, Inc. | Wide area telemetry network |
US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
EP1733735B1 (en) * | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
SE9801923D0 (sv) * | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
ES2299520T3 (es) * | 2000-09-01 | 2008-06-01 | Epigenomics Ag | Procedimiento para la determinacion del grado de metilacion de determinadas citosinas en dna genomico en el contexto secuencial 5'-cpg-3'. |
GB0031079D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Vaccine |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
EP2423335B1 (en) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
DK1450856T3 (da) * | 2001-09-14 | 2010-05-31 | Cytos Biotechnology Ag | Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse |
US7514415B2 (en) | 2002-08-01 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
AU2003213140A1 (en) * | 2002-03-01 | 2003-10-13 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US7758876B2 (en) | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
CA2511538C (en) | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
AU2004226605A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
CN101454451A (zh) * | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | 具有增强免疫刺激能力的c类寡核苷酸类似物 |
KR101138131B1 (ko) * | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
US20060111271A1 (en) * | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
US20060153844A1 (en) | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
JP2008535859A (ja) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
JP5481068B2 (ja) | 2005-08-31 | 2014-04-23 | アメリカ合衆国 | CpGオリゴデオキシヌクレオチドによって誘発される免疫応答を変化させる方法 |
WO2007064478A2 (en) | 2005-11-28 | 2007-06-07 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
MX2008013993A (es) | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
SI2484375T1 (en) | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | A vaccine composition comprising a synthetic adjuvant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
MX2009005849A (es) | 2006-12-04 | 2009-08-12 | Univ Illinois | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. |
US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
CA2713879C (en) * | 2008-02-01 | 2020-01-07 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
WO2009149252A1 (en) * | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
US8728465B2 (en) | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
NZ727616A (en) | 2008-06-27 | 2018-06-29 | Zoetis Services Llc | Novel adjuvant compositions |
US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8053422B2 (en) | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
SG10201400388QA (en) | 2008-12-09 | 2014-05-29 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
NZ593220A (en) * | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US8552165B2 (en) | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
EP2424562B1 (en) * | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
AU2010254550B2 (en) * | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
SG177637A1 (en) | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
US20110064750A1 (en) * | 2009-07-31 | 2011-03-17 | Nabi Biopharmaceuticals | Method and kit for treating nicotine addiction |
SG10201401516XA (en) | 2009-09-03 | 2014-10-30 | Pfizer Vaccines Llc | Pcsk9 vaccine |
JP2011092108A (ja) | 2009-10-30 | 2011-05-12 | Rikkyo Gakuin | シアニジウム類由来のプロトンatpアーゼ遺伝子を用いた耐性植物体の作出方法及び該遺伝子の用途 |
AU2011258156B2 (en) * | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
AU2011259718B2 (en) * | 2010-05-28 | 2016-03-03 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules |
TWI455722B (zh) * | 2010-06-04 | 2014-10-11 | Pfizer Vaccines Llc | 用於預防或治療菸鹼成癮之共軛體 |
EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
SI2699587T1 (sl) * | 2011-04-22 | 2019-08-30 | Wyeth Llc | Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka |
CN104080479B (zh) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
US20150017201A1 (en) * | 2013-03-15 | 2015-01-15 | Regents Of The University Of Minnesota | Novel nicotine dna vaccines |
-
2009
- 2009-12-01 NZ NZ593220A patent/NZ593220A/xx not_active IP Right Cessation
- 2009-12-01 CA CA2745096A patent/CA2745096C/en active Active
- 2009-12-01 RU RU2011122418/10A patent/RU2477753C2/ru active
- 2009-12-01 EP EP09774978.2A patent/EP2376107B1/en active Active
- 2009-12-01 PL PL09774978T patent/PL2376107T3/pl unknown
- 2009-12-01 ES ES09774978.2T patent/ES2481040T3/es active Active
- 2009-12-01 BR BRPI0923341A patent/BRPI0923341B8/pt not_active IP Right Cessation
- 2009-12-01 DK DK09774978.2T patent/DK2376107T3/da active
- 2009-12-01 MX MX2011006088A patent/MX2011006088A/es active IP Right Grant
- 2009-12-01 MY MYPI2015000983A patent/MY172421A/en unknown
- 2009-12-01 JP JP2011540283A patent/JP5016733B2/ja active Active
- 2009-12-01 SI SI200931411A patent/SI2759306T1/sl unknown
- 2009-12-01 MY MYPI2011002378A patent/MY160201A/en unknown
- 2009-12-01 PL PL14161886.8T patent/PL2759306T3/pl unknown
- 2009-12-01 KR KR1020117015657A patent/KR101329374B1/ko active IP Right Grant
- 2009-12-01 SI SI200930939T patent/SI2376107T1/sl unknown
- 2009-12-01 ES ES14161886.8T patent/ES2572563T3/es active Active
- 2009-12-01 EP EP14161886.8A patent/EP2759306B1/en active Active
- 2009-12-01 AU AU2009325926A patent/AU2009325926B2/en not_active Ceased
- 2009-12-01 PE PE2011001201A patent/PE20110998A1/es active IP Right Grant
- 2009-12-01 HU HUE14161886A patent/HUE027823T2/hu unknown
- 2009-12-01 WO PCT/IB2009/055444 patent/WO2010067262A1/en active Application Filing
- 2009-12-01 DK DK14161886.8T patent/DK2759306T3/en active
- 2009-12-01 CN CN200980149607.3A patent/CN102333538B/zh not_active Expired - Fee Related
- 2009-12-01 PT PT97749782T patent/PT2376107E/pt unknown
- 2009-12-01 SG SG2011038270A patent/SG171829A1/en unknown
- 2009-12-07 AR ARP090104733A patent/AR074501A1/es active IP Right Grant
- 2009-12-08 TW TW098141948A patent/TWI370740B/zh not_active IP Right Cessation
-
2011
- 2011-05-26 IL IL213162A patent/IL213162A/en active IP Right Grant
- 2011-05-31 ZA ZA2011/04048A patent/ZA201104048B/en unknown
- 2011-06-10 CO CO11072590A patent/CO6382137A2/es active IP Right Grant
-
2012
- 2012-06-27 HK HK12106265.1A patent/HK1165325A1/xx not_active IP Right Cessation
- 2012-11-27 RU RU2012150453A patent/RU2610690C2/ru active
-
2013
- 2013-06-28 US US13/930,213 patent/US9453059B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012150453A (ru) | Иммуностимулирующие олигонуклеотиды | |
García et al. | An overview of adjuvant formulations and delivery systems | |
US11077184B2 (en) | Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response | |
Apostolico et al. | Adjuvants: classification, modus operandi, and licensing | |
Dowling | Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants | |
Lahiri et al. | Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond | |
Azmi et al. | Recent progress in adjuvant discovery for peptide-based subunit vaccines | |
Amorij et al. | Towards tailored vaccine delivery: needs, challenges and perspectives | |
Rhee et al. | Mucosal vaccine adjuvants update | |
Illum et al. | Chitosan as a novel nasal delivery system for vaccines | |
Salvador et al. | An overview on the field of micro-and nanotechnologies for synthetic peptide-based vaccines | |
Riese et al. | Vaccine adjuvants: key tools for innovative vaccine design | |
CA2370697A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
JP2014522842A5 (ru) | ||
MXPA06012451A (es) | Composiciones y metodos para vacunacion por la mucosa. | |
ES2369550T3 (es) | Formulación de adyuvante para administración en mucosas. | |
Kenney et al. | Adjuvants for the future | |
ES2307958T3 (es) | Uso de un lipopeptido o una lipoproteina como adyuvante en la vacunacion terapeutica o profilactica. | |
Bolhassani et al. | Endogenous and exogenous natural adjuvants for vaccine development | |
Akache et al. | Adjuvants: Engineering protective immune responses in human and veterinary vaccines | |
EP1680446B1 (en) | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens | |
Ott et al. | Development of vaccine adjuvants: a historical perspective | |
Tomai et al. | TLR agonists as vaccine adjuvants | |
Patel et al. | Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment | |
Gheibihayat et al. | Mechanisms and performances of adjuvants in vaccine immunogenicity |